Drug intelligence / Profile preview

SVT-Bax (1-10)

Development stage: Preclinical
Lead developer: Servatus Biopharmaceuticals
Modality: Recombinant Proteins and Enzymes

Overview

SVT-Bax (1-10) is a recombinant protein drug candidate developed by Servatus Biopharmaceuticals. It is being investigated for the treatment of immune system diseases, specifically autoimmune conditions such as psoriasis and rheumatoid arthritis. The drug is in preclinical development and aims to modulate immune responses, potentially offering a novel therapeutic approach for these indications. The precise mechanism of action has not been publicly disclosed.

Beyond the preview

Go deeper on SVT-Bax (1-10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVT-Bax (1-10).

Explore the full profile